Nektar Therapeutics
Nektar Therapeutics' revenue fell 43.9% to $55 million in fiscal 2025. Its operating margin was −253.7%, down from −106.9% a year earlier. Free cash flow was −$209 million. The diluted share count rose 23.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nektar Therapeutics does
Nektar Therapeutics is a research-based drug company that develops medicines that act on the immune system. It has no drug of its own on the market. Its pipeline targets autoimmune diseases, in which the immune system attacks the body's healthy cells, and cancer.
Its lead drug candidate, rezpegaldesleukin, is designed to increase the function of regulatory T cells, immune cells that hold other immune cells in check. It has been tested in atopic dermatitis, a skin disease, and Nektar is studying it in other conditions, including alopecia areata and type 1 diabetes. Nektar says it owns full rights to it after Eli Lilly ended a 2017 license agreement in 2023. Other candidates include NKTR-255 for cancer and NKTR-0165 and NKTR-0166, which are earlier-stage candidates for autoimmune disease.
Nektar has earned revenue from collaboration agreements, such as up-front payments, milestones and royalties. It says that after the Lilly agreement ended it has no collaboration agreement for rezpegaldesleukin, so it expects no partner payments for its lead drug candidates.
Its biggest risks, as it describes them
- It depends heavily on rezpegaldesleukin advancing in clinical studies.
- It needs a lot of capital and expects continued losses.
- Its revenue has come from partners, and it may not strike new partnerships on good terms.
- It relies on contract manufacturers and, for key reagents, a single supplier.
- Competing immunotherapy drugs could make its candidates obsolete.
Income statement
Nektar Therapeutics lost money in fiscal 2025: a net loss of $164 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 734 | 505 | 304 | 255 | 246 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −734 | −505 | −304 | −255 | −246 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 9.3x | 8.0x | 6.5x | 4.3x | 5.0x |
| Quick ratio | 9.2x | 7.7x | 6.1x | 4.3x | 5.0x |
Cash flow
Projections
Project Nektar Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Nektar Therapeutics shares on the open market, and 3 insiders sold $2.4 million, $2.1 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Howard W RobinPresident & CEO, Director | Sold | 418 | $71.98 | $30,088 | Form 4 |
| Aug 18, 2026 | Jonathan ZalevskyChief R&D Officer | Sold | 186 | $71.98 | $13,388 | Form 4 |
| Jun 30, 2026 | Jonathan ZalevskyChief R&D Officer | Sold plan | 5,681 | $70.00 | $397,670 | Form 4 |
| Jun 17, 2026 | Howard W RobinPresident & CEO, Director | Sold plan | 10,000 | $61.19 | $611,880 | Form 4 |
| Jun 16, 2026 | Howard W RobinPresident & CEO, Director | Sold plan | 10,000 | $60.32 | $603,176 | Form 4 |
| Jun 15, 2026 | Jonathan ZalevskyChief R&D Officer | Sold plan | 5,538 | $60.71 | $336,212 | Form 4 |
| May 19, 2026 | Howard W RobinPresident & CEO, Director | Sold | 444 | $65.51 | $29,086 | Form 4 |
| May 19, 2026 | Jonathan ZalevskyChief R&D Officer | Sold | 199 | $65.51 | $13,036 | Form 4 |
| Feb 18, 2026 | Howard W RobinPresident & CEO, Director | Sold | 423 | $73.00 | $30,879 | Form 4 |
| Feb 18, 2026 | Jonathan ZalevskyChief R&D Officer | Sold | 180 | $73.00 | $13,140 | Form 4 |
| Jan 20, 2026 | Jonathan ZalevskyChief R&D Officer | Sold plan | 3,867 | $35.67 | $137,936 | Form 4 |
| Nov 25, 2025 | Howard W RobinPresident & CEO, Director | Sold | 2,207 | $54.28 | $119,796 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 3 of 9 | 2 of 9 |
| Rule of 40 | −216.8% | −170.8% | −421.7% |
| Altman Z'' | −27.81 | −36.33 | −41.60 |
| Accruals ratio | −15.1% | 16.2% | 15.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 2 of 9 | 3 of 9 | 2 of 9 |
Compare
Put Nektar Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 165 | 308 | 1,193 | 115 | 153 | 102 | 92 | 90 | 98 | 55 |
| Revenue growth | −28.3% | 86.0% | 287.8% | −90.4% | 33.4% | −33.4% | −9.7% | −2.1% | 9.2% | −43.9% |
| Gross profit | 135 | 277 | 1,169 | 93 | 133 | 77 | 70 | 56 | 68 | 55 |
| Research and development | 204 | 268 | 400 | 435 | 409 | 400 | 218 | 114 | 121 | 117 |
| Operating income | −113 | −60 | 688 | −440 | −425 | −446 | −376 | −264 | −105 | −140 |
| Net income | −154 | −97 | 681 | −441 | −444 | −524 | −368 | −276 | −119 | −164 |
| Diluted EPS (US$) | −16.50 | −9.30 | 56.70 | −37.80 | −37.35 | −42.90 | −29.55 | −21.75 | −8.68 | −9.73 |
| Diluted shares (millions) | 9 | 10 | 12 | 12 | 12 | 12 | 12 | 13 | 14 | 17 |
| Cash flow | ||||||||||
| Cash from operations | −117 | −80 | 718 | −329 | −313 | −413 | −304 | −193 | −176 | −208 |
| Capital expenditure | 6 | 10 | 14 | 26 | 7 | 15 | 6 | 1 | 2 | 0 |
| Free cash flow | −123 | −90 | 704 | −355 | −321 | −428 | −310 | −193 | −177 | −209 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 26 | 37 | 88 | 100 | 94 | 95 | 57 | 33 | 22 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 60 | 296 | 1,335 | 1,325 | 1,062 | 734 | 505 | 304 | 255 | 246 |
| Debt incl. finance leases | 244 | 245 | 247 | 253 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 569 | 509 | 2,150 | 1,977 | 1,539 | 1,117 | 711 | 398 | 304 | 280 |
| Total liabilities | 481 | 421 | 433 | 572 | 462 | 438 | 344 | 267 | 243 | 191 |
| Shareholders' equity | 88 | 88 | 1,718 | 1,405 | 1,077 | 680 | 367 | 131 | 61 | 90 |
| Margins and ratios | ||||||||||
| Gross margin | 81.7% | 90.1% | 98.0% | 81.3% | 87.3% | 75.6% | 76.5% | 62.5% | 68.8% | 100.0% |
| Operating margin | −68.2% | −19.4% | 57.6% | −383.9% | −278.0% | −437.8% | −408.6% | −292.6% | −106.9% | −253.7% |
| Net margin | −92.8% | −31.4% | 57.1% | −384.5% | −290.6% | −514.0% | −400.0% | −306.3% | −120.9% | −297.1% |
| Free cash flow margin | −74.6% | −29.3% | 59.0% | −309.7% | −209.6% | −419.6% | −336.4% | −214.7% | −180.0% | −377.8% |
| Rule of 40 (growth + FCF margin) | −102.9% | 56.7% | 346.8% | −400.1% | −176.2% | −453.0% | −346.1% | −216.8% | −170.8% | −421.7% |
| Return on capital | −38.4% | −30.5% | 206.1% | −72.2% | — | — | — | — | — | — |
| Return on equity | −324.7% | −109.9% | 75.5% | −28.2% | −35.8% | −59.6% | −70.4% | −111.0% | −124.1% | −217.9% |
| Return on assets | −28.8% | −17.9% | 51.2% | −21.4% | −25.3% | −39.5% | −40.3% | −49.8% | −33.9% | −56.2% |
| Net debt to EBITDA | — | — | −1.6x | — | — | — | — | — | — | — |